Orthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study

Orthocell Ltd ( (AU:OCC) ) has provided an update.

Orthocell has reported new real-world evidence showing its Remplir nerve repair device achieved an overall treatment success rate of 89.7% across 78 procedures in 66 patients, with no post-treatment complications or adverse effects recorded. The study, which covered a broad age range and primarily upper-limb nerve decompression and reconstruction cases, reinforces Remplir’s safety, biocompatibility, and status as a leading nerve wrap in Australia.

The cumulative data indicate Remplir delivered functional muscle recovery in 90.3% of motor nerve reconstructions and significant symptom relief in 89.4% of nerve decompression procedures, with outcomes consistent with prior clinical trial results. Orthocell says the expanding evidence base is driving surgeon adoption, with more than 300 surgeons using Remplir in Australia and growing uptake across over 55 U.S. hospitals, supporting ongoing commercial rollout in the U.S. and planned entry into UK and European markets, subject to future regulatory approvals.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.24 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Ltd is a Perth-based regenerative medicine company focused on advanced biological solutions for nerve and musculoskeletal repair. Its lead product Remplir is a nerve wrap used in decompression and reconstruction procedures, targeting peripheral nerve injuries and compression syndromes in markets including Australia, the U.S., and, pending approvals, Europe and the UK.

Average Trading Volume: 450,569

Technical Sentiment Signal: Hold

Current Market Cap: A$236M

For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.